BIOAF News Alert Bioasis Technologies (BIOAF) 0.8800 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bioasis Technologies (BIOAF) 0.8800 $BIOAF

biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Marketwire - Thu Sep 18, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB" , announces a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B" of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the "Diagnosis and Therapy of Lysosomal Disorders" research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin.

biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
Marketwire - Tue Sep 09, 8:36AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC" , will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme beta-hexosaminidase subunit beta ("HEXB" , which is functionally deficient in sufferers of Sandhoff Disease.

biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis
Marketwire - Thu Sep 04, 8:04AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces that the Natural Sciences and Engineering Research Council of Canada ("NSERC" has awarded a grant to the University of British Columbia ("UBC" in support of the university's collaborative research and development programs with biOasis Technologies Inc. The University and biOasis continue to develop biOasis' extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier ("BBB" for the potential treatment of previously untreatable Central Nervous System ("CNS" diseases and conditions.

biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds
Marketwire - Fri Aug 29, 5:14PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) (the "Company" is please to announce it has closed its non-brokered private placement announced on August 8th, 2014. The Company has issued 1,694,447 units (each a "Unit" , including an over allotment of 94,477 Units, at a price of CDN$0.95 per unit, for gross proceeds of CDN$1,609,753.15. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$1.20 per share for a period of twelve months up to and including August 29th, 2015, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder's fees of CDN$101,460 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until December 30th, 2014. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business.

WSA Talks to Two Dual-Listed Companies Making Waves
Marketwire - Thu Aug 21, 1:00PM CDT
Wall Street Analyzer's CEO Interview Series

biOasis issues up to 1.6m units in non-brokered private placement
M2 - Mon Aug 11, 3:29AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) reported on Friday the launch of a non-brokered private placement of up to 1,600,000 units.

biOasis Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 8:10PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company" announces a non-brokered private placement of up to 1,600,000 units (each a "Unit" at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant" . Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $1.20 per share for a period of twelve months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 Protection of Minority Security Holders in Special Transactions ("MI 61-101" . The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization.

biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
Marketwire - Fri Jul 25, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose.

biOasis Appoints New Chief Financial Officer and Corporate Secretary
Marketwire - Fri Jun 20, 6:30PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of British Columbia Faculty of Law who also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.

biOasis Enters Investor Relations Agreement with Gale Capital Corporation
Marketwire - Mon Jun 16, 8:02AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company" is pleased to announce that is has retained Gale Capital Corporation ("Gale Capital" effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program.

biOasis awarded patent allowances for Lysosomal Storage Disease therapeutic in Europe and Canada
M2 - Fri Mar 28, 3:37AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) disclosed on Thursday the receipt of notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".

biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Marketwire - Thu Mar 27, 8:03AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 141

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 23

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 8

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 149

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 80

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading

Top 5 Most Recently Viewed Articles

Embassy Bancorp, Inc. Reports Strong Financial Growth for Q2

Updated Category News Views 197

Embassy Bancorp, Inc. Financial Results Overview Embassy Bancorp, Inc. (OTCQX: EMYB) has recently released a comprehensive report highlighting its operations and financial achievements for the quarter ended June 30, 2025. The report outlines the ongoing stability and growth of the company, reinforcing its position in the competitive banking landscape. Key Financial...

Continue Reading
Unlocking New Features: Wijmo 2025 v2 by MESCIUS USA, Inc.

Updated Category News Views 200

Wijmo 2025 v2: A Leap Forward in Enterprise Software MESCIUS USA Inc. has officially launched Wijmo 2025 v2, marking the last major release for the year. This version not only promises cutting-edge features but also showcases their commitment to enhancing developer experiences across frameworks. Included in this release is robust support for Angular 20 and Nuxt.js 4,...

Continue Reading
Titan Investors Teams with Corridor for Global Expansion

Updated Category News Views 42

Titan Investors Takes a Bold Leap Forward Alright folks, here's a change in the wind that's got my attention. Titan Investors, a heavyweight in the investment event business, has just locked arms with Corridor Capital. Yeah, we're talking about a private equity firm with a knack for boosting the game of middle-market business services across North America. If you're...

Continue Reading
Examining the Implications of a 'Shadow' Fed Chair Role

Updated Category News Views 166

The Emerging Concept of a ‘Shadow’ Fed Chair There has been growing tension surrounding Chairman Powell, particularly with rising frustration from Donald Trump. Reports indicate that Trump may expedite his decision on Powell's successor, creating anticipation for a so-called 'shadow Fed Chair' who would shape economic opinions until Powell's term concludes in 2026....

Continue Reading
U.S. Postal Service Reports Growth and Financial Improvements

Updated Category News Views 294

U.S. Postal Service Financial Results Overview The U.S. Postal Service has recently shared its financial outcomes for the first quarter of fiscal year 2025, revealing impressive growth metrics that mark a significant turnaround from previous years. Controllable income has doubled to $968 million, a substantial increase from $472 million during the same period last year,...

Continue Reading